The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Quest Diagnostics' revenue will improve 2.0% and EPS will improve 4.5%.
The average estimate for revenue is $1.94 billion. On the bottom line, the average EPS estimate is $1.17.
Last quarter, Quest Diagnostics notched revenue of $1.94 billion. GAAP reported sales were 6.3% higher than the prior-year quarter's $1.82 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.07. GAAP EPS were $0.99 for Q1 compared to -$0.33 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 42.5%, 220 basis points better than the prior-year quarter. Operating margin was 16.5%, 100 basis points better than the prior-year quarter. Net margin was 8.2%, 1,120 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $7.71 billion. The average EPS estimate is $4.59.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 547 members out of 580 rating the stock outperform, and 33 members rating it underperform. Among 181 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 174 give Quest Diagnostics a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quest Diagnostics is hold, with an average price target of $61.53.
- Add Quest Diagnostics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Motley Fool newsletter services have recommended buying shares of Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Dividend Stocks in Gene Sequencing
Looking for dividend stocks in the gene sequencing field? Check out General Electric, Roche, and Quest Diagnostics.
IBM's Watson Is Tackling Medicine's Most Complex Problems
Some of the biggest companies in medicine are enlisting IBM to help solve medicine's toughest problems with Watson AI.
Better Buy: Exact Sciences Corporation vs. Quest Diagnostics
Does recent news for Exact Sciences make it a better buy now than this diagnostic industry heavyweight?